Form 4 Filing for BioAge Labs, Inc.

This filing details a Form 4 submission for BioAge Labs, Inc. concerning James Healy, a director. On June 10, 2026, Mr. Healy was granted 22,000 stock options with a right to buy at a price of $0.00 per share, exercisable at $15.48. These options are set to expire on June 9, 2036. The vesting conditions stipulate that the entire option award shall vest on the earlier of the next annual meeting of the Issuer's stockholders or the one-year anniversary of the grant date, contingent upon Mr. Healy's continued service to the Issuer. The post-transaction shares owned by Mr. Healy following this grant are 22,000. The filing was signed on June 12, 2026, by Dov A. Goldstein as attorney-in-fact.